Skip to main
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is well-positioned to capitalize on the growing demand for portable and remote cardiac monitoring solutions, with its proprietary and patented 12-lead ECG technology and solid progress in clinical development and regulatory approvals. The recent 1Q results, including expanded commercial launch and progress in developing an extended-wear ECG patch to detect ischemia, demonstrate the company's commitment to innovation and addressing unmet needs in the market. With a multi-billion-dollar opportunity and a capital-efficient sales model, HeartBeam has the potential for strong financial performance and growth in the coming years. However, there are market development risks, including the potential for slower adoption of remote monitoring solutions, that may impact the company's growth trajectory.

Bears say

HeartBeam is currently facing numerous risks to its business, including potential failure of its device and software in clinical trials and commercial success, as well as dilution risk and the need for additional capital financing. In addition, the company's financial results for 1Q26, including a net loss of $4.7M and no revenue, are below expectations. Despite partnerships with ClearCardio and Atelier Health, revenue recognition is not expected until 2H26, and there are potential risks related to competition, regulatory approvals, and physician adoption. While HeartBeam has a strong intellectual property portfolio, ongoing innovation and enforcement may be necessary in the face of competition from larger companies in the remote cardiac monitoring space.

HeartBeam (BEAT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.